Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REGRANEX vs CARISOPRODOL COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes chemotaxis and proliferation of fibroblasts, smooth muscle cells, and other cells involved in wound healing, and stimulates granulation tissue formation.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have adequate blood supply.,Off-label: pressure ulcers, venous stasis ulcers, other chronic wounds.
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
Apply topically once daily, a thin layer to the full area of the ulcer, using a measured amount of gel based on ulcer length and width in centimeters: (length × width × 0.5) grams.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
Terminal half-life ~30-60 minutes after topical application; prolonged in renal impairment (up to 2-3 hours). Clinical context: Short systemic exposure limits off-target effects.
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Metabolized locally; no systemic metabolism expected due to topical administration and minimal absorption. If absorbed, degraded by proteolytic enzymes at the wound site.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Primarily renal; minimal biliary/fecal. Becaplermin is cleared renally (>90% as metabolites) with <2% excreted unchanged. Fecal elimination accounts for <10%.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
~25% bound to plasma proteins (primarily albumin).
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
Vd ~12 L (~0.17 L/kg assuming 70 kg), indicating limited extravascular distribution due to molecular size.
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Topical: Negligible systemic bioavailability (<1% of applied dose absorbed; increased with large wounds or impaired skin barrier).
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
No dose adjustment required for renal impairment.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
No dose adjustment required for hepatic impairment.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Safety and efficacy in pediatric patients have not been established; use not recommended.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
No specific dose adjustment recommended; use with caution due to potential comorbidities and polypharmacy.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
Increased risk of mortality secondary to malignancy in patients treated with 3 or more tubes of REGRANEX (becaplermin) Gel. A postmarketing study showed increased mortality from cancer in patients who used three or more tubes of REGRANEX compared to control patients. REGRANEX should only be used when the benefits can be expected to outweigh the risks. REGRANEX is not recommended in patients with known malignancy.
None
Application to wounds with active malignancy may promote tumor growth. Application to wounds with infection or necrotic tissue should be discontinued until infection is controlled or necrotic tissue debrided. Potential for immunogenicity.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Known hypersensitivity to becaplermin or any product component. Application to wounds with known neoplasms or active malignancy. Use on wounds closed by primary intention.
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
No known food interactions. Regranex is applied topically and has minimal systemic absorption.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
No adequate and well-controlled studies in pregnant women. Animal studies at doses 25-100 times human exposure show no fetal harm. Risk cannot be ruled out; use only if potential benefit justifies potential risk.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
It is not known whether becaplermin is excreted in human milk. M/P ratio unknown. Use caution; consider developmental and health benefits of breastfeeding along with mother's clinical need for REGRANEX.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
No pharmacokinetic data in pregnancy. Dosage adjustments are not recommended based on current knowledge; use same dosing as non-pregnant adults.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
Regranex (becaplermin) is a recombinant platelet-derived growth factor (PDGF) gel indicated for diabetic neuropathic ulcers extending into subcutaneous tissue or deeper. Ensure ulcer is free of infection, necrotic tissue, and has adequate blood supply before initiating therapy. Apply a thin layer once daily, and recalibrate gel amount based on ulcer dimensions (length x width x 0.5 for cm to grams). Do not use on wounds with exposed bone, tendon, or joint. Monitor for increased risk of malignancy; contraindicated in patients with active malignancies. The gel is for single-patient use only; discard tube 30 days after opening.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Wash hands before and after applying Regranex.,Clean the ulcer gently with saline or water before each application.,Apply a thin layer of gel (about 1/16 inch) to the entire ulcer area once daily.,Cover the ulcer with a saline-moistened gauze dressing after applying gel.,Do not use more than the prescribed amount or frequency.,Store Regranex in the refrigerator; do not freeze.,Discard any unused gel in the tube 30 days after first opening.,Report any signs of infection (increased pain, redness, swelling, foul odor) or new skin changes around the wound.,You may need to have your wound measured weekly to adjust the gel amount.,Avoid applying other creams, ointments, or lotions to the same area.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REGRANEX vs CARISOPRODOL COMPOUND, answered by our medical review team.
REGRANEX is a Topical Growth Factor (Platelet-Derived) that works by Recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes chemotaxis and proliferation of fibroblasts, smooth muscle cells, and other cells involved in wound healing, and stimulates granulation tissue formation.. CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REGRANEX and CARISOPRODOL COMPOUND depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REGRANEX is: Apply topically once daily, a thin layer to the full area of the ulcer, using a measured amount of gel based on ulcer length and width in centimeters: (length × width × 0.5) grams.. The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REGRANEX and CARISOPRODOL COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REGRANEX is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies at doses 25-100 times human exposure show no fetal harm. Risk cannot be ruled out; use only if potential b. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.